SkyCell, a Zurich, Switzerland-based pharmaceutical supply chain tech company, raised US$57M in funding.
The round was led by Catalyst.
The company intends to use the funds to expand its global footprint following a sustained period of growth for the business, with compound growth of more than 55% over the last three years.
Led by CEO Richard Ettl, SkyCell is a purpose-led technology company innovating the pharmaceutical supply chain through a combination of proprietary software, hardware, and big data. It manufactures temperature-controlled door-to-door container solutions that allow pharma companies to optimise their supply chain by reducing, and even predicting, the risks associated with delivering sensitive drugs by air. Its proprietary software solution combines simulation data with operational data (S+O data), enabling pharma companies to have real-time, end-to-end oversight of every shipment around the world, and its automated approval capability reduces quality approval time from an average of 14 days to just hours, getting drugs to consumers faster.
As of today, the company transports more than US$1.5bn of pharma goods per month delivering hundreds of million doses of vaccines, cancer treatments, diabetes care and diagnostic solutions to patients around the world.
FinSMEs
31/10/2023